– Welcome – Sophia Karagiannis, King’s College London, Guy’s Hospital, London, UK
– AllergoOncology Working Group update and plans  – Erika Jensen-Jarolim, Medical University Vienna, Vienna, Austria
– Danger signals in Allergy and Oncology – Christoph Bergmann, ENT Research Institute for Clinical Studies, Essen, Germany

– CpG adjuvant in vaccination and immunotherapy: Which lessons have we learned? – Markus Ollert, Department of Infection and Immunity,LIH, Luxembourg
– Alterations of the gastrointestinal barrier act as danger signals in allergy and oncology – Eva Untersmayr, Immunologist, University of Vienna, Austria

– Eosinphils supressing NK cell anti-tumor potential: Innate immune checkpoints – Martijn Schuijs, PhD, Ghent University, Belgium
– Basophils in allergy and beyond – Mariona Pascal, Hospital Clínic, Universitat de Barcelona, Spain
– Desensitization to Chemotherapy/biologicals and in vitro models: from the bench to the bedside – Leticia de las Vecillas, University Hospital La Paz, Madrid, Spain

– Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming – Oscar Palomares, Complutense University of Madrid, Spain
– Macrophages/Allergy/Cancer – Elena Izquierdo, PhD, CEU San Pablo University, Madrid, Spain
– Don’t stop me now: the intimate relationship between macrophages and antibodies in allergy and cancer – Rodolfo Bianchini, Medical University of Vienna, Austria

– TLRs, T cells, allergen immunotherapy – Mohamed Shamji, Imperial College London,UK
– IgE/IgG4 in allergy/cancer – Mübeccel Akdis, University of Zurich, Switzerland
– Allergic airway inflammation impacts tumor take and delays experimental glioblastoma progression – Aurélie Poli, Luxembourg Institute of Health, Luxembourg